Login to Your Account

New Clinical Trial Mandate Poses Concerns for Drug Firms

By Donna Young

Monday, March 24, 2008
Reports that clinical trial data were being suppressed led Congress last fall to pass legislation requiring drugmakers to submit study information, other than Phase I, to a publicly accessible registry and results database. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription